Scientists discover how molecule becomes anticancer weapon

Years of toil in the laboratory have revealed how a marine bacterium makes a potent anti-cancer molecule.

The anti-cancer molecule salinosporamide A, also called Marizomb, is in Phase III clinical trials to treat glioblastoma, a brain cancer. Scientists now for the first time understand the enzyme-driven process that activates the molecule.

Researchers at UC San Diego's Scripps Institution of Oceanography found that an enzyme called SalC assembles what the team calls the salinosporamide anti-cancer "warhead." Scripps graduate student Katherine Bauman is the lead author of a paper that explains the assembly process in the March 21 issue of Nature Chemical Biology.

The work solves a nearly 20-year riddle about how the marine bacterium makes the warhead that is unique to the salinosporamide molecule and opens the door to future biotechnology to manufacture new anti-cancer agents.

"Now that scientists understand how this enzyme makes the salinosporamide A warhead, that discovery could be used in the future to use enzymes to produce other types of salinosporamides that could attack not only cancer but diseases of the immune system and infections caused by parasites," said co-author Bradley Moore, a Distinguished Professor at Scripps Oceanography and the Skaggs School of Pharmacy and Pharmaceutical Sciences.

Salisporamide has a long history at Scripps and UC San Diego. Microbiologist Paul Jensen and marine chemist Bill Fenical of Scripps Oceanography discovered both salinosporamide A and the marine organism that produces the molecule after collecting the microbe from sediments of the tropical Atlantic Ocean in 1990. Some of the clinical trials over the course of the drug’s development took place at Moores Cancer Center at UC San Diego Health.

"This has been a very challenging 10-year project," said Moore, who is Bauman's advisor. "Kate's been able to bring together 10 years’ worth of earlier work to get us across the finish line."

A big question for Bauman was to find out how many enzymes were responsible for folding the molecule into its active shape. Are multiple enzymes involved or just one?

"I would have bet money on more than one. In the end, it was just SalC. That was surprising," she said.

Moore says the salinosporamide molecule has a special ability to cross the blood-brain barrier, which accounts for its progress in clinical trials for glioblastoma. The molecule has a small but complex ring structure. It starts as a linear molecule that folds into a more complex circular shape.

"The way nature makes it is beautifully simple. We as chemists can't do what nature has done to make this molecule, but nature does it with a single enzyme," he said.

The enzyme involved is common in biology; it is one that participates in the production of fatty acids in humans and antibiotics like erythromycin in microbes.

Bauman, Percival Yang-Ting Chen of Morphic Therapeutics in Waltham, Mass., and Daniella Trivella of Brazil’s National Center for Research in Energy and Materials, determined the molecular structure of SalC. For this purpose they used the Advanced Light Source, a powerful particle accelerator that generates x-ray light, at the U.S. Department of Energy’s Lawrence Berkeley National Laboratory.

"The SalC enzyme performs a reaction very different from a normal ketosynthase," Bauman said. A normal ketosynthase is an enzyme that helps a molecule form a linear chain. SalC, by contrast, manufactures salinosporamide by forming two complex, reactive, ring structures.

A single enzyme can form both of those ring structures that are hard for synthetic chemists to make in the lab. Armed with this information, scientists now can mutate the enzyme until they find forms that show promise for suppressing various types of disease.

The marine bacterium involved, called Salinispora tropica, makes salinosporamide to avoid being eaten by its predators. But scientists have found that salinosporamide A also can treat cancer. They have isolated other salinosporamides, but salinosporamide A has features that the others lack - including biological activity that makes it hazardous to cancer cells.

"Inhibiting that proteasome makes it a great anti-cancer agent," said Bauman, speaking of the protein complex that degrades useless or impaired proteins. But there's another type of proteasome found in immune cells. What if scientists could devise a slightly different salinosporamide than salinosporamide A? One that poorly inhibits the cancer-prone proteasome but excels at inhibiting the immunoproteasome? Such a salinosporamide could be a highly selective treatment for autoimmune diseases, the type that causes the immune system to turn upon the very body it should protect.

"That’s the idea behind generating some of these other salinosoporamides. And access to this enzyme SalC that installs the complicated ring structure opens the door to that in the future," Bauman said.

As Bauman’s list of co-authors attests, Moore’s group began working on this project more than a decade ago. Former Moore Lab postdoctoral scientists who contributed are Tobias Gulder of Germany's Technical University of Dresden; Daniela Trivella of Brazil’s National Center for Research in Energy and Materials; and Percival Yang-Ting Chen of Morphic Therapeutics in Waltham, Mass. Vikram V. Shende is a current postdoctoral scientist in the Moore Lab. The other two co-authors are longtime collaborators on the project: Sreekumar Vellalath and Daniel Romo of Baylor University.

Bauman's work is funded by a National Research Service Award from the National Institutes of Health. Further funding was provided by the Robert A. Welch Foundation and the São Paulo Research Foundation.

Bauman, K.D., Shende, V.V., Chen, P.YT. et al.
Enzymatic assembly of the salinosporamide γ-lactam-β-lactone anticancer warhead.
Nat Chem Biol, 2022. doi: 10.1038/s41589-022-00993-w

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...